Busulfex (busulfan) is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. It functions as a bifunctional alkylating agent, releasing reactive carbonium ions upon hydrolysis, which damage DNA and induce cytotoxicity. Pharmacokinetic studies demonstrated that 93% of patients receiving 0.8 mg/kg every six hours for 16 doses maintained AUC values below the target. The drug achieves concentrations in the cerebrospinal fluid comparable to plasma levels and primarily binds to albumin. Metabolism occurs through conjugation with glutathione, catalyzed by glutathione S-transferase (GST), followed by oxidative metabolism in the liver. Approximately 30% of the administered 14C-labeled busulfan is excreted in the urine. A prospective clinical trial involving 61 patients with various hematologic malignancies showed that all patients experienced myeloablation, with a median time to neutropenia of 4 days, and all evaluable patients engrafted at a median of 13 days post-transplant. The recommended adult dose is 0.8 mg per kg intravenously as a two-hour infusion every six hours for four days, administered in combination with cyclophosphamide. Premedication with anticonvulsants is recommended to prevent seizures.